9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays

ConditionPeritoneal MesotheliomaEstimated Enrollment: 33Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: RetrospectiveStudy ID Numbers: D50828Study First Received: April 27, 2016Last Updated: July 25, 2016Estimated Primary Completion Date: January 2016Primary Outcome Measures:BAP1 mutationsSponsors and Collaborators:Hospices Civils de LyonResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02834234...

Continue reading

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

ConditionMalignant Pleural MesotheliomasEstimated Enrollment: 50Age Group: 39 Years to 84 Years   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: RetrospectiveStudy ID Numbers: DR-81Study First Received: October 28, 2015Last Updated: May 29, 2016Estimated Primary Completion Date: May 2016Primary Outcome Measures:to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival|assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result...

Continue reading

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 11Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 09-142Study First Received: December 2, 2009Last Updated: April 21, 2015Estimated Primary Completion Date: July 2012Primary Outcome Measures:To Determine the Rate of Clinical Benefit (i.e. Rate of Complete or Partial Response Plus Stable Disease) at 16 Weeks for Patients With Malignant Mesothelioma Treated With Everolimus as Second or Third Line Therapy.Sponsors and Collaborators:Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals|Dana-Farber Cancer Institute|University of PennsylvaniaResult Received: April 7, 2015Website Link: https://ClinicalTrials.gov/show/NCT01024946...

Continue reading

Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 20Age Group: 20 Years to 75 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 10512|H3E-JE-ME02Study First Received: October 10, 2006Last Updated: April 10, 2007Estimated Primary Completion Date: nullPrimary Outcome Measures:To investigate safety profile when administered pemetrexed combined with cisplatin in malignant pleural mesothelioma patients|To investigate efficacy when administered pemetrexed combined with cisplatin in malignant pleural mesothelioma patientsSponsors and Collaborators:Eli Lilly and CompanyResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00386815...

Continue reading

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 19Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 2005-0288|NCI-2012-01381Study First Received: November 20, 2006Last Updated: November 16, 2015Estimated Primary Completion Date: February 2014Primary Outcome Measures:Maximum Tolerated Dose (MTD) of Cisplatin, Pemetrexed, and Imatinib Mesylate Given to Participants with Unresectable or Metastatic Malignant MesotheliomaSponsors and Collaborators:M.D. Anderson Cancer Center|NovartisResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00402766...

Continue reading

Tomotherapy Treatment for Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 18Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: LU-11-0077 / 22933Study First Received: May 2, 2007Last Updated: April 5, 2016Estimated Primary Completion Date: May 2015Primary Outcome Measures:Quality of Life|Breathing Function|Survival/Response RateSponsors and Collaborators:AHS Cancer Control AlbertaResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00469196...

Continue reading

Serum Biomarkers in Diagnosis of Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 230Age Group: 18 Years to 85 Years   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case-Only|Time Perspective: RetrospectiveStudy ID Numbers: 2010-280-1Study First Received: January 6, 2014Last Updated: January 6, 2014Estimated Primary Completion Date: December 2010Primary Outcome Measures:Serum N-ERC/mesothelin, C-ERC/mesothelin, hyaluronan, osteopontin and syndecan -1 level in the patients with mesothelioma, metastatic malignant pleural diseases, benign pleural diseases, and benign asbestos pleurisy.Sponsors and Collaborators:Eskisehir Osmangazi UniversityResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02029105...

Continue reading

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 37Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 03-369Study First Received: August 29, 2005Last Updated: December 23, 2011Estimated Primary Completion Date: March 2007Primary Outcome Measures:To determine the response to the combination of bevacizumab and erlotinib in previously treated malignant mesothelioma|To determine the time to tumor progression|to determine the duration of response|to determine the median and overall survival of patients|to determine the safety of the drugs administeredSponsors and Collaborators:Dana-Farber Cancer Institute|Massachusetts General Hospital|University of ChicagoResult Received: No Study Results PostedWebsite Link:...

Continue reading